International Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China; National Center for Liver Cancer, Shanghai, China; Mengchao Hepatobiliary Hospital, Fujian Medical University, Fuzhou, China.
International Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China; National Center for Liver Cancer, Shanghai, China.
Cancer Lett. 2018 Jan 1;412:283-288. doi: 10.1016/j.canlet.2017.10.008. Epub 2017 Oct 16.
Liver cancer ranks the sixth in cancer incidence and the second in tumor related mortality worldwide, with over half of the new cases and deaths occur in China. Because of difficulties in early diagnosis, rapid progression and lack of targeted drugs, the survival rate of liver cancer is extremely low. The existence of extraordinary heterogeneity has greatly limited the progress in early detection, molecular classification and targeted therapy of live cancer, owing to its varied risk factors, genetic susceptibilities, morphological diversity and microenvironmental discrepancies. Based on the heterogeneity of individual patients, precision medicine brings a new dimension to cancer personalized diagnosis and more-targeted treatment, and even give us access to pre-clinical screening of tumors in high risk populations. The present review article will provide progresses in precision diagnosis, molecular classification, signaling disregulation, preclinical models and personalized treatment of liver cancer in China.
肝癌在全球范围内的癌症发病率中排名第六，肿瘤相关死亡率排名第二，超过一半的新发病例和死亡病例发生在中国。由于早期诊断困难、进展迅速且缺乏靶向药物，肝癌的生存率极低。由于其存在显著的异质性，极大地限制了肝癌的早期检测、分子分类和靶向治疗的进展，这归因于其不同的危险因素、遗传易感性、形态多样性和微环境差异。基于个体患者的异质性，精准医学为癌症的个体化诊断和更具针对性的治疗带来了新的维度，甚至使我们能够对高危人群中的肿瘤进行临床前筛查。本文综述了中国在肝癌精准诊断、分子分类、信号失调、临床前模型和个体化治疗方面的进展。
